Jason Kessler1, Kelly Ruggles1, Anik Patel1,2, Kimberly Nucifora1, Lifeng Li1, Mark S Roberts3, Kendall Bryant4, R Scott Braithwaite1. 1. Department of Population Health, NYU School of Medicine, New York, New York. 2. Department of Medicine, University of British Columbia, Vancouver, BC, Canada. 3. Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania. 4. National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland.
Abstract
BACKGROUND: In the current report, we ask if targeting a cognitive behavioral therapy (CBT)-based intervention aimed at reducing hazardous alcohol consumption to HIV-infected persons in East Africa would have a favorable value at costs that are feasible for scale-up. METHODS: Using a computer simulation to inform HIV prevention decisions in East Africa, we compared 4 different strategies for targeting a CBT intervention-(i) all HIV-infected persons attending clinic; (ii) only those patients in the pre-antiretroviral therapy (ART) stages of care; (iii) only those patients receiving ART; and (iv) only those patients with detectable viral loads (VLs) regardless of disease stage. We define targeting as screening for hazardous alcohol consumption (e.g., using the Alcohol Use Disorders Identification Test and offering the CBT intervention to those who screen positive). We compared these targeting strategies to a null strategy (no intervention) or a hypothetical scenario where an alcohol intervention was delivered to all adults regardless of HIV status. RESULTS: An intervention targeted to HIV-infected patients could prevent 18,000 new infections, add 46,000 quality-adjusted life years (QALYs), and yield an incremental cost-effectiveness ratio of $600/QALY compared to the null scenario. Narrowing the prioritized population to only HIV-infected patients in pre-ART phases of care results in 15,000 infections averted, the addition of 21,000 QALYs and would be cost-saving, while prioritizing based on an unsuppressed HIV-1 VL test results in 8,300 new infections averted, adds 6,000 additional QALYs, and would be cost-saving as well. CONCLUSIONS: Our results suggest that targeting a cognitive-based treatment aimed at reducing hazardous alcohol consumption to subgroups of HIV-infected patients provides favorable value in comparison with other beneficial strategies for HIV prevention and control in this region. It may even be cost-saving under certain circumstances.
BACKGROUND: In the current report, we ask if targeting a cognitive behavioral therapy (CBT)-based intervention aimed at reducing hazardous alcohol consumption to HIV-infectedpersons in East Africa would have a favorable value at costs that are feasible for scale-up. METHODS: Using a computer simulation to inform HIV prevention decisions in East Africa, we compared 4 different strategies for targeting a CBT intervention-(i) all HIV-infectedpersons attending clinic; (ii) only those patients in the pre-antiretroviral therapy (ART) stages of care; (iii) only those patients receiving ART; and (iv) only those patients with detectable viral loads (VLs) regardless of disease stage. We define targeting as screening for hazardous alcohol consumption (e.g., using the Alcohol Use Disorders Identification Test and offering the CBT intervention to those who screen positive). We compared these targeting strategies to a null strategy (no intervention) or a hypothetical scenario where an alcohol intervention was delivered to all adults regardless of HIV status. RESULTS: An intervention targeted to HIV-infectedpatients could prevent 18,000 new infections, add 46,000 quality-adjusted life years (QALYs), and yield an incremental cost-effectiveness ratio of $600/QALY compared to the null scenario. Narrowing the prioritized population to only HIV-infectedpatients in pre-ART phases of care results in 15,000 infections averted, the addition of 21,000 QALYs and would be cost-saving, while prioritizing based on an unsuppressed HIV-1 VL test results in 8,300 new infections averted, adds 6,000 additional QALYs, and would be cost-saving as well. CONCLUSIONS: Our results suggest that targeting a cognitive-based treatment aimed at reducing hazardous alcohol consumption to subgroups of HIV-infectedpatients provides favorable value in comparison with other beneficial strategies for HIV prevention and control in this region. It may even be cost-saving under certain circumstances.
Authors: Rebecca K Papas; John E Sidle; Benson N Gakinya; Joyce B Baliddawa; Steve Martino; Michael M Mwaniki; Rogers Songole; Otieno E Omolo; Allan M Kamanda; David O Ayuku; Claris Ojwang; Willis D Owino-Ong'or; Magdalena Harrington; Kendall J Bryant; Kathleen M Carroll; Amy C Justice; Joseph W Hogan; Stephen A Maisto Journal: Addiction Date: 2011-08-18 Impact factor: 6.526
Authors: Helene A C M Voeten; Omar B Egesah; Mark Y Ondiege; Corlien M Varkevisser; J Dik F Habbema Journal: Sex Transm Dis Date: 2002-08 Impact factor: 2.830
Authors: Godfrey Bigogo; Allan Audi; Barrack Aura; George Aol; Robert F Breiman; Daniel R Feikin Journal: Int J Infect Dis Date: 2010-08-25 Impact factor: 3.623
Authors: Ronald S Braithwaite; Kimberly A Nucifora; Jason Kessler; Christopher Toohey; Lingfeng Li; Sherry M Mentor; Lauren M Uhler; Mark S Roberts; Alison Galvani; Kendall Bryant Journal: J Acquir Immune Defic Syndr Date: 2014-06-01 Impact factor: 3.731
Authors: Rebecca K Papas; Benson N Gakinya; Michael M Mwaniki; Hana Lee; Alfred K Keter; Steve Martino; Debra A Klein; Tao Liu; Michelle P Loxley; John E Sidle; Kathryn Schlaudt; Tobista Nafula; Victor M Omodi; Joyce B Baliddawa; Daniel W Kinyanjui; Stephen A Maisto Journal: Addiction Date: 2020-07-13 Impact factor: 6.526
Authors: Kelly V Ruggles; Anik R Patel; Stephen Schensul; Jean Schensul; Kimberly Nucifora; Qinlian Zhou; Kendall Bryant; R Scott Braithwaite Journal: PLoS One Date: 2017-09-05 Impact factor: 3.240
Authors: Noah Kiwanuka; Ali Ssetaala; Ismail Ssekandi; Annet Nalutaaya; Paul Kato Kitandwe; Julius Ssempiira; Bernard Ssentalo Bagaya; Apolo Balyegisawa; Pontiano Kaleebu; Judith Hahn; Christina Lindan; Nelson Kaulukusi Sewankambo Journal: PLoS One Date: 2017-02-16 Impact factor: 3.240
Authors: Natalie A Blackburn; Vivian F Go; Quynh Bui; Heidi Hutton; Radhika P Tampi; Teerada Sripaipan; Tran Viet Ha; Carl A Latkin; Shelley Golden; Carol Golin; Geetanjali Chander; Constantine Frangakis; Nisha Gottfredson; David W Dowdy Journal: AIDS Behav Date: 2021-01-03
Authors: Anik R Patel; Kelly V Ruggles; Kimberly Nucifora; Qinlian Zhou; Stephen Schensul; Jean Schensul; Kendall Bryant; R Scott Braithwaite Journal: MDM Policy Pract Date: 2018-10-16